Kaneka Acquires Japan Medical Device Technology
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has acquired all shares of Japan Medical Device Technology Co., Ltd. (Headquarters: Kamimashiki-gun, Kumamoto; President: Shuzo Yamashita) (hereinafter JMDT), a developer and manufacturer of medical devices, on November 30, 2023, and made it a wholly owned subsidiary.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206372197/en/
Stent before expansion (Photo: Business Wire)
Kaneka manufactures and sells endovascular catheters, which are devices used in the treatment of cardiac, peripheral vascular, and cerebrovascular diseases. In particular, stenting*1 for the treatment of coronary artery diseases such as atherosclerosis has a market worth 30 billion yen in Japan, and Kaneka is aiming to expand its business in this area.
JMDT has high technological capabilities in the research and development of coronary stents and is one of the leaders in the development of bioresorbable stents*2.
Coronary artery treatment usually involves the placement of a tubular metal mesh stent at the lesion to expand the lumen and restore blood flow. However, as the stent remains in the blood vessel, another stent often cannot be placed in the same location should restenosis recur. JMDT's bioresorbable stent is made of a biodegradable magnesium alloy, which prevents vessel blockage potentially caused by the stent remaining in the vessel. In addition, 95% of the stent is resorbed and taken up by the body 1.5 years after implantation, ensuring that it does not interfere with the treatment of restenosis.
*1. A stent is a small, expandable, and tubular metal mesh, often made of metals such as cobalt-chromium alloy or nickel-titanium alloy. It is a medical device that widens tubular parts of the human body (blood vessels, trachea, esophagus, duodenum, colon, biliary tract, etc.) from inside the lumen. They are mounted on a catheter and dilated inside arteries to treat narrowed or occluded coronary arteries or peripheral arteries in the lower extremities. Implanting a stent restores blood flow at the treatment site.
*2. JMDT's bioresorbable stent is made of a highly safe magnesium alloy and has a low risk of thrombosis with a thin (100 µm) yet fully expandable stent body. Its surface is coated with a layer that controls the degradation of the magnesium alloy and drug (Sirolimus) elution. Furthermore, it is currently the only bioresorbable stent in Japan that has progressed to the FIH (First In Human) trial for use in humans for the first time.
|
[Japan Medical Device Technology Co., Ltd.] |
|
|
Representative: |
Shuzo Yamashita |
|
Capital Stock: |
10 million yen |
|
Headquarters: |
Kumamoto Techno Incubation Center Bldg. D, 2020-3 Tabaru, |
|
|
Mashiki-machi, Kamimashiki-gun, Kumamoto, 861-2202 |
|
Foundation: |
October 2014 |
|
Business: |
Research and development for coronary stents and commissioned development of other medical devices |
Introduction video of the bioresorbable stent (by JMDT):
https://www.youtube.com/watch?v=CrFBhuQCIf4
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231206372197/en/
Contact information
KANEKA CORPORATION
Investors & Public Relations Department
Chika Harada
Info_Pro@kaneka.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
10-Year Partnership Between ISN ® and Yara International Enhances Ongoing Commitment to Contractor Safety14.5.2025 11:00:00 EEST | Press release
ISN, the global leader in contractor and supplier information management services, celebrates 10 years of partnership with the European division of Yara International (Yara), a leading provider of crop nutrition and sustainable agricultural solutions. After a successful implementation in the Americas, Yara adopted ISNetworld across its European sites in 2015, expanding its use of the contractor management platform, streamlining processes, and improving operational efficiency. “Over the past decade, ISN has been instrumental to Yara’s contractor management processes in Norway and the Netherlands," said Steinar Bjelland, Procurement Manager at Yara. "Leveraging ISNetworld tools and services such as RAVS 360™ and acknowledgment form tracking, along with ISN’s multilingual support, has helped Yara optimise compliance, improve communication, and effectively align our protocols with industry best practices.” Headquartered in Oslo, Norway, Yara operates in more than 60 countries. Yara works t
Ares Management Opens Milan Office14.5.2025 11:00:00 EEST | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the opening of a new office in Milan, the firm’s latest office in Europe. The office will enhance Ares’ access to the Italian market, and its ability to raise and invest capital across its strategies, particularly within its European Direct Lending business, as well as the Wealth Management and European Real Estate platforms. This latest opening underscores Ares’ commitment to a highly localized approach to investing in Europe, which the firm entered in 2007 through the opening of a London office, followed by Paris, Frankfurt and Stockholm in 2009 and, most recently, Amsterdam and Madrid in 2019. Across its investment strategies, including European Direct Lending and European Real Estate, Ares has deployed over €1.6 billion to support Italian businesses and assets, as of March 31, 2025, and Ares expects to accelerate this activity in the coming years. Tyrone Cooney, Partn
Intelsat, Cubic³ Complete Vehicle Satellite Connectivity Test, Advancing Ubiquitous Connectivity Vision14.5.2025 10:00:00 EEST | Press release
Intelsat and Cubic³ have successfully completed a critical vehicle satellite connectivity test, marking a significant milestone in their joint mission to create a seamless connectivity service for all types of vehicles. The test demonstrated successful integration between Intelsat satellites and Cubic³’s software platform, showcasing how terrestrial and non-terrestrial networks can seamlessly link to deliver always-on connectivity regardless of location. “Our Memorandum of Understanding and successful test brings us closer to our vision of truly ubiquitous connectivity,” said Bruno Fromont, Intelsat Chief Technology Officer. “By combining Intelsat’s satellite expertise with Cubic³’s innovative connectivity platform, we’re creating solutions that will keep vehicles connected anywhere in the world, enabling critical functions from broadband connectivity, diagnostics to eventually supporting autonomous driving capabilities.” The successful test focused on a commercial land mobile use case
Norli Liv & Pension Modernizes Investment Operations with Clearwater Analytics14.5.2025 10:00:00 EEST | Press release
Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced that Danish pension provider, Norli Liv & Pension, part of the Norli group, has partnered with Clearwater to modernize its investment accounting, reporting and compliance operations. Clearwater will provide Norli with a single, consolidated view of all in-house and outsourced chief investment officer (OCIO) managed holdings across its public and private asset classes—enhancing investment transparency and empowering better, faster decision-making. The platform will also support regulatory compliance through automated workflows and robust, audit-ready reporting. By moving to Clearwater’s single instance, multi-tenant platform, Norli Liv & Pension will eliminate multiple legacy platforms, reduce manual work and accelerate its monthly close. The platform’s “single pane of glass” view will provide users across departments with unified access to accurate, timely data and a
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)14.5.2025 09:14:00 EEST | Press release
GSK plc (LSE/NYSE: GSK) and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, today announced that they have entered into an agreement under which GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic liver disease (SLD). Under the agreement, GSK will pay $1.2 billion upfront, with potential for additional success-based milestone payments totalling $800 million. Efimosfermin is a novel, once-monthly fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), including cirrhosis, and future development in alcohol-related liver disease (ALD), both forms of SLD. Given efimosfermin’s direct antifibrotic mechanism of action and GSK’s dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom